搜索
Kodiak Sciences Inc
KOD添加自选
41.010USD
-2.670-6.11%
收盘 05/08, 16:00（美东）报价延迟15分钟
2.57B总市值
亏损市盈率 TTM
关于 Kodiak Sciences Inc 公司
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc简介
公司代码KOD
公司名称Kodiak Sciences Inc
上市日期Oct 04, 2018
CEOPerlroth (Victor)
员工数量109
证券类型Ordinary Share
年结日Oct 04
公司地址1250 Page Mill Rd
城市PALO ALTO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94304
电话16502810850
网址https://kodiak.com/
公司代码KOD
上市日期Oct 04, 2018
CEOPerlroth (Victor)
Kodiak Sciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
+13.50%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
+13.50%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 5月10日 周日
更新时间: 5月10日 周日
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
31.83%
Perlroth (Victor D)
4.79%
BlackRock Institutional Trust Company, N.A.
4.71%
Braidwell LP
3.31%
State Street Investment Management (US)
2.77%
其他
52.60%
持股股东
持股股东
占比
Baker Bros. Advisors LP
31.83%
Perlroth (Victor D)
4.79%
BlackRock Institutional Trust Company, N.A.
4.71%
Braidwell LP
3.31%
State Street Investment Management (US)
2.77%
其他
52.60%
股东类型
持股股东
占比
Hedge Fund
45.55%
Investment Advisor
22.85%
Investment Advisor/Hedge Fund
15.33%
Individual Investor
5.18%
Research Firm
3.11%
Private Equity
1.36%
Endowment Fund
1.11%
Pension Fund
0.23%
Bank and Trust
0.18%
其他
5.10%
机构持股
更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
311
60.04M
96.04%
+7.96M
2025Q4
265
48.79M
79.98%
+1.64M
2025Q3
248
41.93M
79.39%
-9.11M
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
19.92M
32.66%
+2.61M
+15.07%
Dec 31, 2025
Perlroth (Victor D)
3.00M
4.91%
+300.00K
+11.13%
Mar 25, 2026
BlackRock Institutional Trust Company, N.A.
2.95M
4.83%
+546.31K
+22.77%
Dec 31, 2025
Braidwell LP
2.07M
3.4%
+2.07M
--
Dec 31, 2025
State Street Investment Management (US)
1.73M
2.84%
+899.57K
+108.06%
Dec 31, 2025
RTW Investments L.P.
1.49M
2.44%
+1.49M
--
Dec 31, 2025
TCG Crossover Management, LLC
1.45M
2.37%
+300.00K
+26.19%
Dec 31, 2025
ICONIQ Capital, LLC
1.27M
2.08%
--
--
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.14M
1.86%
+673.93K
+145.42%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Fidelity Enhanced Small Cap ETF
0.18%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Russell 2000 Value ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.05%
ProShares Hedge Replication ETF
0.03%
ProShares UltraPro Russell2000
0.03%
Proshares Ultra Russell 2000
0.02%
查看更多
Fidelity Enhanced Small Cap ETF
占比0.18%
iShares Micro-Cap ETF
占比0.11%
Vanguard US Momentum Factor ETF
占比0.11%
Invesco RAFI US 1500 Small-Mid ETF
占比0.06%
iShares Health Innovation Active ETF
占比0.06%
iShares Russell 2000 Value ETF
占比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.05%
ProShares Hedge Replication ETF
占比0.03%
ProShares UltraPro Russell2000
占比0.03%
Proshares Ultra Russell 2000
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
